Modified release tacrolimus

Yonsei Medical Journal

Volumn 45, Issue 6, 2004, Pages 1127-1131

  First, M Roy ^a   Fitzsimmons, William E ^a  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Immunosuppression; Kidney transplantation; Tacrolimus

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MULTIPLE DRUG DOSE; PATIENT COMPLIANCE; RECIPIENT; SINGLE DRUG DOSE; STEADY STATE; SUSTAINED RELEASE FORMULATION; VOLUNTEER;

EID: 12344292602     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2004.45.6.1127     Document Type: Article

References (27)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12.
2. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002;346:580-90.
3. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002;62:311-8.
4. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002;73: 775-82.
5. Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002;73:732-6.
6. Margreiter R. for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002;359: 741.
7. Mayer AD for the European Tacrolimus Multicentre Renal Study Group. Chronic rejection and graft half-life: five-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc 2002;34:1491-2.
8. First MR. Renal function as a predictor of long-term graft survival in renal transplant patients. Nephrol Dial Transplant 2003;18 (Suppl 1):3-6.
9. Jurewicz WA. Tacrolimus versus ciclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003;18 (Suppl 1):7-11.
10. Didlake RH, Dreyfus K, Kerman RH, Van Buren CT, Kahan BD. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 1988;20 (Suppl 3):63-9.
11. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after transplantation: a systematic review. Transplantation 2004;77:769-76.
12. UNOS Market Share Report, February, 2004.
13. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977-83.
14. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997;64:436.
15. Miller J. Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. Transplant Proc 1999;31:276-7.
16. First MR, Fitzsimmons WE. New drugs to improve transplant outcomes. Transplantation 2004:77:S88.
17. Package insert for tacrolimus (Prograf®) from Fujisawa Healthcare, Inc. Revised July 2001.
18. Data on file. Company Report 98-0-048, Fujisawa Healthcare, Inc., 2001.
19. Data on file. Company Report 00-0-076, Fujisawa Healthcare, Inc., 2001.
20. Data on file. Company Report 00-0-077, Fujisawa Healthcare, Inc., 2001.
21. Data on file. Company Report 00-0-078, Fujisawa Healthcare, Inc., 2001.
22. Data on file. Company Report FG-506-04-21, Fujisawa Healthcare, Inc., 2001.
23. Data on file. Company Report FG-506-04-25, Fujisawa Healthcare, Inc., 2002.
24. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. US Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); July 2002.
25. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. US Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); March 2003; BP Revision 1.
26. Alloway R, for the Tacrolimus Modified Release Kidney Conversion Study Group. Conversion of stable kidney transplant recipients from a twice daily Prograf based regimen to a once daily modified release tacrolimus based regimen. Am J Transplant 2004;4 (Suppl 8):230 (Abstract).
27. Florman S, for the Tacrolimus Modified Release Liver Conversion Study Group. Conversion of stable liver transplant recipients from a twice daily Prograf based regimen to a once daily modified release tacrolimus based regimen. Am J Transplant 2004;4 (Suppl 8):268 (Abstract).